1. |
Capon MR, Polkinghorne PJ, Fitzke FW, et al. Sorsby's pseudoinflammatory macula dystrophy: Sorsby's fundus dystrophies[J]. Eye, 1988, 2(Pt 1): 114-122. DOI: 10.1038/eye.1988.23.
|
2. |
郭丽莉, 黎晓新, 梁建宏. Sorsby眼底营养不良[J]. 国际眼科纵览, 2006, 30(3): 156-158. DOI: 10.3760/cma.j.issn.1673-5803.2006.03.004.Guo LL, Li XX, Liang JH. Sorsby's fundus dystrophy[J]. Int Rev Ophthalmol, 2006, 30(3): 156-158. DOI: 10.3760/cma.j.issn.1673-5803.2006.03.004.
|
3. |
Jacobson SG, Cideciyan AV, Bennett J, et al. Novel mutation in the TIMP3 gene causes Sorsby fundus dystrophy[J]. Arch Ophthalmol, 2002, 120(3): 376-379. DOI: 10.1001/archopht.120.3.376.
|
4. |
Sivaprasad S, Webster AR, Egan C, et al. Clinical course and treatment outcomes of Sorsby fundus dystrophy[J]. Am J Ophthalmol, 2008, 146(2): 228-234. DOI: 10.1016/j.ajo.2008.03.024.
|
5. |
尹小芳, 叶祖科, 汤秀容, 等. Sorsby眼底营养不良一家系[J]. 中华眼底病杂志, 2018, 34(6): 546-551. DOI: 10.3760/cma.j.issn.1005-1015.2018.06.005.Yin XF, Ye ZK, Tang XR, et al. A pedigree of Sorsby fundus dystrophy with mutation in TIMP3 gene[J]. Chin J Ocul Fundus Dis, 2018, 34(6): 546-551. DOI: 10.3760/cma.j.issn.1005-1015.2018.06.005.
|
6. |
Rahman N, Georgiou M, Khan KN, et al. Macular dystrophies: clinical and imaging features, molecular genetics and therapeutic options[J]. Br J Ophthalmol, 2020, 104(4): 451-460. DOI: 10.1136/bjophthalmol-2019-315086.
|
7. |
Fung AT, Stöhr H, Weber BHF, et al. Atypical sorsby fundus dystrophy with a novel Tyr159cys Timp-3 mutation[J]. Retin Cases Brief Rep, 2013, 7(1): 71-74. DOI: 10.1097/ICB.0b013e318267101e.
|
8. |
Gliem M, Müller PL, Mangold E, et al. Sorsby fundus dystrophy: novel mutations, novel phenotypic characteristics, and treatment outcomes[J]. Invest Ophthalmol Vis Sci, 2015, 56(4): 2664-2676. DOI: 10.1167/iovs.14-15733.
|
9. |
Jacobson SG, Cideciyan AV, Regunath G, et al. Night blindness in Sorsby's fundus dystrophy reversed by vitamin A[J]. Nat Genet, 1995, 11(1): 27-32. DOI: 10.1038/ng0995-27.
|
10. |
Weber BH, Vogt G, Wolz W, et al. Sorsby's fundus dystrophy is genetically linked to chromosome 22q13-qter[J]. Nature Genet, 1994, 7(2): 158-161. DOI: 10.1038/ng0694-158.
|
11. |
Christensen DRG, Brown FE, Cree AJ, et al. Sorsby fundus dystrophy-a review of pathology and disease mechanisms[J]. Exp Eye Res, 2017, 165: 35-46. DOI: 10.1016/j.exer.2017.08.014.
|
12. |
Felbor U, Stöhr H, Amann T, et al. A novel Ser156Cys mutation in the tissue inhibitor of metalloproteinases-3 (TIMP3) in Sorsby's fundus dystrophy with unusual clinical features[J]. Hum Mol Genet, 1995, 4(12): 2415-2416. DOI: 10.1093/hmg/4.12.2415.
|
13. |
Carrero-Valenzuela RD, Klein ML, Weleber RG, et al. Sorsby fundus dystrophy. A family with the Ser181Cys mutation of the tissue inhibitor of metalloproteinases 3[J]. Arch Ophthalmol, 1996, 114(6): 737-738. DOI: 10.1001/archopht.1996.01100130729016.
|
14. |
Felbor U, Stöhr H, Amann T, et al. A second independent Tyr168Cys mutation in the tissue inhibitor of metalloproteinases-3(TIMP3) in Sorsby's fundus dystrophy[J]. J Med Genet, 1996, 33(3): 233-236. DOI: 10.1136/jmg.33.3.233.
|
15. |
Bakall B, Sohn EH, Riley J, et al. Novel mutations and change ofnomenclature for pathogen icvariants in the TIMP3 gene causing Sorsby fundus dystrophy[J/OL]. Invest Ophthalmol Vis Sci, 2014, 55: 3290[2014-04-01]. https://iovs.arvojournals.org/article.aspx?articleid=2268700.
|
16. |
Schoenberger SD, Agarwal A. A novel mutation at the N-terminaldomain of the TIMP3 gene in Sorsby fundus dystrophy[J]. Retina, 2013, 33(2): 429-435. DOI: 10.1097/IAE.0b013e318263d3b4.
|
17. |
Saihan Z, Li Z, Rice J, et al. Clinical and biochemical effects of the E139K missense mutation in the TIMP3 gene, associated with Sorsby fundus dystrophy[J]. Mol Vis, 2009, 15: 1218-1230.
|
18. |
Langton KP, McKie N, Curtis A, et al. A novel tissue inhibitor of metalloproteinases-3 mutation reveals a common molecular phenotype in Sorsby's fundus dystrophy[J]. J Biol Chem, 2000, 275(35): 27027-27031. DOI: 10.1074/jbc.M909677199.
|
19. |
Barbazetto IA, Hayashi M, Klais CM, et al. A novel TIMP3 mutation associated with Sorsby fundus dystrophy[J]. Arch Ophthalmol, 2005, 123(4): 542-543. DOI: 10.1001/archopht.123.4.542.
|
20. |
Baston A, Gerhardt C, Zandi S, et al. Visual outcome after Intravitreal anti-VEGF therapy for macular neovascularisation secondary to Sorsby's fundus dystrophy: a systematic review[J/OL]. J Clin Med, 2021, 10(11): 2433[2021-05-30]. https://pubmed.ncbi.nlm.nih.gov/34070857/. DOI: 10.3390/jcm10112433.
|
21. |
Gemenetzi MK, Luff AJ, Lotery AJ. Successful treatment of choroidal neovascularization secondary to Sorsby fundus dystrophy with intravitreal Bevacizumab[J]. Retin Cases Brief Rep, 2011, 5(2): 132-135. DOI: 10.1097/ICB.0b013e3181cc216b.
|
22. |
Gray TL, Wong HC, Raymond GL. Choroidal neovascularization secondary to Sorsby fundus dystrophy treated with intravitreal Bevacizumab[J]. Retin Cases Brief Rep, 2012, 6(2): 193-196. DOI: 10.1097/ICB.0b013e31822476fd.
|
23. |
Balaskas K, Hovan M, Mahmood S, et al. Ranibizumab for the management of Sorsby fundus dystrophy[J]. Eye, 2013, 27(1): 101-102. DOI: 10.1038/eye.2012.221.
|
24. |
Copete-Piqueras S, Cava-Valenciano C, Flores-Moreno I, et al. Tratamiento antiangiogénico en fondo de distrofia de Sorsby sin mutación en gen de TIMP-3[J]. Arch Soc Españ ola Oftalmol, 2013, 88(6): 240-243. DOI: 10.1016/j.oftal.2011.12.005.
|
25. |
Kapoor KG, Bakri SJ. Intravitreal anti-vascular endothelial growth factor therapy for choroidal neovascularization due to Sorsby macular dystrophy[J]. J Ocul Pharmacol Ther, 2013, 29(4): 444-447. DOI: 10.1089/jop.2011.0206.
|
26. |
Keller J, Giralt J, Alforja S, et al. Altering the clinical course of Sorsby fundus dystrophy with the use of anti-vascular endothelial growth factor intraocular therapy[J]. Retin Cases Brief Rep, 2015, 9(2): 104-105. DOI: 10.1097/ICB.0000000000000103.
|
27. |
Mohla A, Khan K, Kasilian M, et al. OCT angiography in the management of choroidal neovascular membrane secondary to Sorsby fundus dystrophy[J/OL]. BMJ Case Rep, 2016, 2016: bcr2016216453[2016-09-01]. https://casereports.bmj.com/content/2016/bcr-2016-216453.long. DOI: 10.1136/bcr-2016-216453.
|
28. |
Menassa N, Burgula S, Empeslidis T, et al. Bilateral choroidal neovascular membrane in a young patient with Sorsby fundus dystrophy: the value of prompt treatment[J/OL]. BMJ Case Rep, 2017, 2017: bcr2017220488[2017-08-03]. https://pubmed.ncbi.nlm.nih.gov/28775088/. DOI: 10.1136/bcr-2017-220488.
|
29. |
Tsokolas G, Almuhtaseb H, Lotery A. Evaluation of Pro-re-Nata (PRN) and treat and extend Bevacizumab treatment protocols in Sorsby fundus dystrophy[J]. Eur J Ophthalmol, 2018, 30(1): 26-33.
|
30. |
Kaye R, Lotery A. Long-term outcome of Bevacizumab therapy in Sorsby fundus dystrophy, a case series[J]. Investig Ophthalmol Vis Sci, 2017, 58: 229.
|
31. |
Sanz GF, Alonso-Gonzalez R, Keane P, et al. Treatment with intravitreal an-ti-VEGF for choroidal neovascular membrane secondary to Sorsby's fundus dystrophy: a 24-month analysis[J/OL]. Invest Ophthal Vis Sci, 2013, 54: 3863[2013-06-01]. https://iovs.arvojournals.org/article.aspx?articleid=2148681.
|
32. |
Hoskin A, Sehmi K, Bird AC. Sorsby's pseudoinflammatory macular dystrophy[J]. Brit J Ophthal, 1981, 65(12): 859-865. DOI: 10.1136/bjo.65.12.859.
|
33. |
Klenotic PA, Munier FL, Marmorstein LY, et al. Tissue inhibitor of metalloproteinases-3 (TIMP-3) is a binding partner of epithelial growth factor-containing fibulin-like extracellular matrix protein 1 (EFEMP1). Implications for macular degenerations[J]. J Biol Chem, 2004, 279(29): 30469-30473. DOI: 10.1074/jbc.M403026200.
|